CJC-1295 no-dac mod grf 1-29 is a synthetic 29-amino acid tetrasubstituted analog of growth hormone-releasing hormone (GHRH 1-29). Designed to enhance plasma stability while maintaining physiological, pulsatile growth hormone secretion, it selectively binds to GHRH receptors on anterior pituitary somatotrophs. Preclinical models evaluate its capacity to sustain serum growth hormone and downstream IGF-1 levels for cellular repair and metabolic signaling research.
CJC-1295 no-dac mod grf 1-29 is a synthetic 29-amino acid tetrasubstituted analog of growth hormone-releasing hormone (GHRH 1-29). Designed to enhance plasma stability while maintaining physiological, pulsatile growth hormone secretion, it selectively binds to GHRH receptors on anterior pituitary somatotrophs. Preclinical models evaluate its capacity to sustain serum growth hormone and downstream IGF-1 levels for cellular repair and metabolic signaling research.
Mod GRF 1-29, officially designated as modified growth releasing factor 1-29 and frequently referenced alongside CJC-1295 no dac (mod grf 1-29), represents a truncated, chemically optimized derivative of endogenous endogenous GHRH(1-44). The native peptide GHRH(1-29) contains the fully functional catalytic core required for GHRH receptor activation, but it suffers from a rapid physiological half-life in vitro and in vivo (less than 12 minutes) due to immediate enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV) between the Alanine-2 and Aspartate-3 positions.
To engineering greater metabolic resistance, researchers substituted four amino acid residues within the sequence: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These specific modifications hinder DPP-IV cleavage while preserving high binding affinity to the GHRH receptor. In comparative assays, this tetrasubstituted configuration extends plasma stability from minutes to approximately 30 minutes, allowing investigators to observe physiological somatotroph activation without altering the receptor's downstream conformation. For a comprehensive overview of related peptide signaling cascades, explore our GHRH analogs guide.
In vitro functional assays confirm that cjc-1295 no-dac mod grf 1-29 acts as a selective full agonist at the human and rodent GHRH receptor, a G-protein-coupled receptor (GPCR) predominantly expressed on the cell surface of anterior pituitary somatotrophs. Ligand engagement triggers intracellular activation of adenylate cyclase, elevating cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This signaling cascade prompts both the immediate exocytosis of stored growth hormone (GH) vesicles and the transcription of new GH mRNA.
Unlike non-pulsatile secretion models, Mod GRF 1-29 maintains natural physiological GH pulsatility. Because its extended biological activity remains within a sub-hour window, it does not induce receptor desensitization, downregulation, or continuous, unphysiological GH elevation. Investigators comparing GHRH pathways can review detailed molecular documentation across our growth hormone secretagogues hub.
A critical distinction in secretagogue research involves the comparison of dac:grf (CJC-1295 with Drug Affinity Complex) versus Mod GRF 1-29 (CJC-1295 without DAC). The Drug Affinity Complex (DAC) is a maleimidopropionic acid moiety covalently bound to the Lysine residue at position 30, enabling the peptide to bind irreversibly to serum albumin in circulation. This extends the half-life of CJC-1295 DAC to over 6 to 8 days, producing sustained, elevated baseline growth hormone levels.
Conversely, researchers seeking to observe discrete, pulsatile release profiles without long-term systemic elevation select CJC-1295 No DAC. In direct comparative preclinical models, pairing Mod GRF 1-29 with growth hormone secretagogue receptor (GHSR) agonists such as Ipamorelin, Sermorelin, or GHRP-6 yields synergistic secretagogue responses, whereas CJC-1295 DAC operates via continuous baseline stimulation.
When purchasing compounds for rigorous analytical or cell-culture protocols, verifying structural integrity and chemical purity is mandatory. Low-purity peptide samples introduce uncontrolled artifacts into receptor binding assays, cell viability studies, and metabolic profiling. Laboratories conducting quantitative research must require lot-specific documentation prior to study initiation.
PX1 Research enforces stringent quality benchmarks across all production lots. Every vial of cjc-1295 no-dac mod grf 1-29 is manufactured in USA-based, GMP-compliant facilities and tested by ISO 17025 accredited third-party laboratories. Quality verification requires reverse-phase high-performance liquid chromatography (RP-HPLC) showing chemical purity ≥98.0%, electrospray ionization mass spectrometry (ESI-MS) confirming exact molecular mass (3367.9 Da), and chromogenic LAL assays validating bacterial endotoxin levels strictly below <0.5 EU/mg. Institutional buyers managing bulk procurement can access dedicated supply channels via our wholesale portal.
Lyophilized cjc-1295 no-dac mod grf 1-29 requires careful reconstitution to maintain peptide tertiary structure and prevent aggregation. Researchers should perform reconstitution under a laminar flow hood utilizing sterile laboratory-grade solvents. Standard diluents include Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution, depending on downstream assay compatibility.
To reconstitute, slowly introduce the diluent along the inner glass wall of the vial, allowing the solvent to saturate the lyophilized cake. Gentle swirl motion is recommended; aggressive agitation, vortexing, or sonication can denature the peptide backbone. Reconstituted solutions should be aliquoted into low-protein-binding microcentrifuge tubes to prevent adsorption loss during sub-zero storage cycles. For technical reference materials, visit the PX1 Research library.
Lyophilized CJC-1295 No-DAC remains stable when stored at -20°C to -80°C in a desiccated environment protected from light exposure. Under these conditions, structural integrity is maintained for up to 24 months. Frequent freeze-thaw cycles must be avoided, as thermal cycling promotes peptide cleavage and formation of insoluble aggregates.
Following reconstitution, liquid aliquots stored at 2°C to 8°C exhibit biochemical stability for up to 30 days when formulated with bacteriostatic preservatives. Unpreserved aqueous solutions must be used immediately within acute in vitro protocols. Long-term storage of reconstituted liquid solutions, even at low temperatures, is not recommended due to hydrolysis risks over extended timelines.
Preclinical investigation frequently examines the synergistic interaction between GHRH analogs and Growth Hormone Secretagogue Receptor (GHSR-1a) agonists. When Mod GRF 1-29 is evaluated in combination with ghrelin mimetics, studies observe a multi-fold amplification of growth hormone release compared to either compound administered in isolation.
This synergy stems from distinct intracellular pathways: GHRH activation stimulates intracellular cAMP via the Gs-alpha subunit, while GHSR-1a activation triggers intracellular calcium ion influx via the Gq-protein coupled pathway. Combined stimulation leads to enhanced pituitary somatotroph vesicle fusion. Researchers exploring dual-pathway protocols can review linked data on synergistic peptide combinations or review individual reagents such as Ipamorelin.
In animal models, transient elevations in growth hormone induced by CJC-1295 No-DAC lead to downstream hepatic transcription and secretion of Insulin-like Growth Factor 1 (IGF-1). IGF-1 acts as a primary mediator of cellular proliferation, protein synthesis, collagen deposition, and nitrogen retention in musculoskeletal tissues.
Researchers examine Mod GRF 1-29 in preclinical settings investigating tendon healing, skeletal muscle regeneration, bone mineral density accrual, and lipid oxidation mechanisms. Because Mod GRF 1-29 preserves normal physiological negative feedback loops driven by circulating somatostatin and IGF-1, it serves as a valuable control model for studying natural endocrine regulation.
Securing consistent, fully documented research reagents is essential for reproducible scientific outcomes. PX1 Research serves universities, biotechnology firms, and independent research institutions by providing batch-tested compounds supported by complete analytical documentation.
All orders ship directly from centralized fulfillment centers in California and Arizona. Qualified orders processed Monday through Friday before cut-off thresholds ship the same day, ensuring minimal transit time for sensitive lyophilized materials. Every shipment includes lot-matched Certificates of Analysis accessible via digital batch verification.
What is cjc-1295 no-dac mod grf 1-29?
CJC-1295 No-DAC (also known as Mod GRF 1-29) is a synthetic 29-amino acid peptide analog of Growth Hormone-Releasing Hormone (GHRH). It features four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that increase resistance to enzymatic degradation by DPP-IV while preserving physiological, pulsatile growth hormone secretagogue activity in research models.
Where can laboratories buy cjc-1295 no-dac mod grf 1-29 with verified purity?
Laboratories can buy CJC-1295 No-DAC Mod GRF 1-29 directly from PX1 Research. Every batch undergoes third-party analytical testing by ISO 17025 accredited laboratories, providing verified purity levels of ≥98.0% via RP-HPLC, molecular weight verification via mass spectrometry, and endotoxin analysis.
What factors determine the price and purchase of mod grf 1-29 peptide?
The price and purchase of mod grf 1-29 peptide are determined by synthesis scale, purity thresholds (≥98%), manufacturing compliance (USA GMP-compliant facilities), and the depth of third-party analytical verification (HPLC chromatograms, ESI-MS, and endotoxin testing per lot).
How can international researchers evaluate mod grf 1-29 peptide online kopen parameters?
International researchers seeking to order or evaluate 'mod grf 1-29 peptide online kopen' standard specifications should verify that the supplier provides lot-specific Certificates of Analysis (COA), ISO 17025 testing documentation, verified purity ≥98%, and temperature-controlled laboratory shipping protocols.
What protocols apply when research labs plan to bestellen mod grf 1-29 peptide online?
When laboratories plan to 'bestellen mod grf 1-29 peptide online', procurement managers must ensure the compound is sourced strictly for in vitro and preclinical laboratory research use only. Reviewing supplier accreditation, HPLC purity curves, and endotoxin limits (<0.5 EU/mg) ensures scientific validity.
What criteria should be checked when looking to kopen mod grf 1-29 peptide online?
Investigators intending to 'kopen mod grf 1-29 peptide online' must check for: 1) USA-based manufacturing, 2) HPLC and Mass Spectrometry documentation per lot, 3) Endotoxin testing compliance, and 4) Clear distinction between Mod GRF 1-29 (No DAC) and CJC-1295 with DAC.
How should research institutions evaluate suppliers matching query terms like kopen mod grf 1-29 peptide?
Institutions evaluating suppliers under terms like 'kopen mod grf 1-29 peptide' should select vendors like PX1 Research that provide full analytical transparency, ISO 17025 certified batch reporting, and fast dispatch from dedicated domestic facilities.
How do international laboratories interact with queries like mod grf 1-29 ペプチドショップ?
Global laboratories searching terms such as 'mod grf 1-29 ペプチドショップ' require high-purity, laboratory-grade reagents with standardized international shipping compliance, sealed moisture-resistant packaging, and verified analytical documentation.
Where do institutional researchers go to buy mod grf 1-29?
Institutional researchers buy Mod GRF 1-29 from specialized scientific suppliers like PX1 Research, which provides documented purity (≥98.0%), lot-traceability, and reliable same-day dispatch M-F from California and Arizona facilities.
What is the key difference between dac:grf and cjc-1295 no dac (mod grf 1-29)?
The key difference between dac:grf and CJC-1295 No-DAC is the presence of the Drug Affinity Complex (DAC). DAC binds covalently to serum albumin, extending the half-life to over 6 days for continuous GH elevation. CJC-1295 No-DAC (Mod GRF 1-29) lacks this complex, resulting in a ~30-minute half-life that preserves physiological pulsatile GH release.
What should laboratories check when preparing to buy mod grf 1-29 peptide?
When preparing to buy mod grf 1-29 peptide, verify that the compound is supplied in lyophilized form, accompanied by a lot-specific COA showing RP-HPLC and ESI-MS results, endotoxin levels <0.5 EU/mg, and proper storage handling instructions.
How should CJC-1295 No-DAC be reconstituted and stored in a laboratory setting?
CJC-1295 No-DAC should be reconstituted using sterile Bacteriostatic Water or 0.9% sodium chloride, allowing the solvent to run down the inner glass wall without vortexing. Store lyophilized vials at -20°C to -80°C. Once reconstituted, store solution aliquots at 2°C to 8°C for up to 30 days.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.